The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
From cancer research to diagnostic solutions
The Theme of the event was 'Building One Health Together – Improving Health Equity'
The meeting provides recommendations to the G20 and its Member States and international partners on the establishment of a R&D and manufacturing network for diagnostics
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Affordability is key to providing accessible healthcare for Bharat.
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Clinical Decision Support Systems' huge potential to help ensure that each patient can receive high-quality care; study shows a reduction in diagnostic errors from 24% to 2%
Subscribe To Our Newsletter & Stay Updated
